Theragenics Reports Revenue and Earnings for Third Quarter 2012

Tools

Theragenics Reports Revenue and Earnings for Third Quarter 2012

 

BUFORD, Ga.--()--Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the third quarter ended September 30, 2012.

"In our surgical products segment customer behavior is erratic but open orders have remained similar to past trends. Overall our large customer base remains intact"

Consolidated Results and Highlights

  • Consolidated revenue of $19.9 million in the third quarter, down 5% from 2011
  • Earnings per share
    • $0.02 in the third quarter compared to $0.03 in 2011
    • Modified Dutch auction share repurchase in July 2012 had no effect on reported EPS for third quarter 2012
  • Adjusted EBITDA of $3.2 million in the third quarter compared to $4.0 million in 2011
  • Cash flow from operations of $4.3 million in the third quarter compared to $3.6 million in 2011
  • Renewed credit facility with Wells Fargo in October 2012
    • Increased maximum available borrowings to $40 million and reduced interest rate to LIBOR plus 1.75% with maturity date of October 2015
  • Repurchased 4,761,904 common shares for $10.0 million in July 2012 pursuant to our modified Dutch auction tender offer. Total cost including transaction costs was approximately $10.4 million.
  • Cash, cash equivalents and marketable securities were $31.8 million and credit facility borrowings were $22.0 million at September 30, 2012, resulting in a net positive position of $9.8 million

Segment Results

  • Revenue
    • Surgical products revenue of $14.2 million in the third quarter, down 7% from 2011
    • Brachytherapy revenue of $5.8 million in the third quarter, down 4% from 2011
      • Incremental revenue in the Brachytherapy segment from acquired Core customers was $1.0 million in the third quarter of 2012
  • Operating income
    • Surgical products operating income of $243,000 in the third quarter, compared to $780,000 in 2011
    • Brachytherapy operating income of $906,000 in the third quarter, compared to $1.2 million in 2011

Comments

"Headwinds continue in all four of our business units," stated M. Christine Jacobs, Chairman and CEO. "The medical device sector in which we reside is facing a triple threat of healthcare reform fallout, an impending medical device tax and macroeconomic uncertainty. Theragenics intends to weather this triple threat by continuing our plans for long term organic growth, improving profitability and conservative cash flow management."

"In our surgical products segment customer behavior is erratic but open orders have remained similar to past trends. Overall our large customer base remains intact," remarked Ms. Jacobs.

Ms. Jacobs continued, "In our brachytherapy business, palladium revenue declined year over year due to an industry wide decline in prostate cancer procedures that we do not believe is specific to brachytherapy. Recent press reports indicate more men are opting for no screening or no treatment at all. These reports are consistent with what we are hearing and affect all treatment types. As an upside, our recent Core transaction partially offset the decline in palladium revenue by increasing our iodine sales contribution to revenue and profitability."

"We had two additional events this quarter," Ms. Jacobs stated. "We completed our $10 million share repurchase in July, which was funded entirely from cash on hand. We also renewed our credit facility in October with terms more favorable than our previous credit facility. We couldn't have accomplished these important tasks had our balance sheet and operations been wanting. Indeed, our position and ability to weather current headwinds is strong."

Ms. Jacobs concluded, "Our short and long-term plans to address these threats include consolidating functions across the company, eliminating redundancies, seeking out opportunities and reducing costs."

Tables I and II to this press release contain condensed consolidated statements of earnings and balance sheets. Segment information, including revenue and operating income by segment, is summarized in Table III. Table IV includes a reconciliation of GAAP reported net earnings to net earnings before interest, taxes, depreciation, amortization and share-based compensation (Adjusted EBITDA). Table V includes a detail of our pre-tax charges for special items.

Theragenics will host a conference call today at 11:00 a.m. Eastern Time. To access the call, dial 877-407-4019 or 201-689-8337. This call is also being broadcast live over the Internet, and a recording will be available for one month on our website. To access the webcast, log on to www.theragenics.com and select "Company Presentations" under Investor Relations or follow this link: http://edge.media-server.com/m/p/jn8dfdpo/lan/en. You also can access a phone replay of the call until midnight November 15, 2012 by dialing 877-660-6853 or 201-612-7415 and entering the conference ID 402905.

Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. The surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, radiofrequency devices, implanters, introducer products, and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics' brachytherapy business manufactures, markets and distributes "seeds" used primarily in the minimally invasive treatment of localized prostate cancer. The Company's brachytherapy product line (www.theragenicsbrachy.com) includes its palladium-103 TheraSeed® device and its iodine-125 AgX100™ device. The terms "Company," "we," "us," or "our" mean Theragenics Corporation and all entities included in our consolidated financial statements. For additional information, call our Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.

This press release contains disclosure of earnings before interest, taxes, depreciation, amortization and share-based compensation (which we refer to as "Adjusted EBITDA"). We believe Adjusted EBITDA provides an additional and meaningful assessment of our ongoing results and performance. Because we have historically reported what we currently refer to as Adjusted EBITDA, we also believe that the inclusion of this non-GAAP measure provides consistency in our financial reporting and facilitates investors' understanding of our historical operating trends by providing an additional basis for comparisons to prior periods. In addition to measures such as net income and operating income as calculated and presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"), we utilize Adjusted EBITDA, among other things, 1) to establish financial and operational goals; 2) to monitor our actual performance in relation to our business plan and operating budgets; 3) to understand key trends; 4) to make operational decisions and allocate resources; and 5) as part of several components we consider in determining incentive compensation. We believe presentation of Adjusted EBITDA provides supplemental information that is helpful to an understanding of the operating results of our businesses and period-to-period comparisons of performance. However, we recognize that the use of non-GAAP measures has limitations, including the fact that they may not be directly comparable with similar non-GAAP financial measures used by other companies. We compensate for these limitations by providing reconciliation to the most directly comparable GAAP financial measure. All non-GAAP financial measures are intended to supplement the applicable GAAP disclosures and should not be considered in isolation from, or as substitute for, financial information prepared in accordance with GAAP. For a reconciliation of non-GAAP measures from GAAP reported amounts, please refer to Table IV to this press release.

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future growth, opportunities and investments, pipeline, incremental brachytherapy revenue growth, the expected effect of the Core asset acquisition on our results, and anticipated positive results in general. From time to time we may make other forward-looking statements relating to other matters, including without limitation, expected total purchase price of the Core asset acquisition, research and development plans, investments in our surgical products and brachytherapy businesses and capital expenditures. Actual results may differ materially due to a variety of factors, including, among other things, uncertainties related to the integration of acquired companies and assets into our organization, the timing and the ability to capitalize on opportunities for investment and growth within our surgical products business, ability to recognize value from areas of shared expertise, risks and uncertainties related to competition within the medical device industry, development and growth of new applications within the markets for wound closure, vascular access, specialty needle, brachytherapy and, more broadly, medical devices, competition from other companies within the wound closure, vascular access, specialty needle, brachytherapy and medical device markets, competition from other methods of treatment, new product development cycles (pipeline), effectiveness and execution of marketing and sales programs, changes in product pricing, changes in costs of materials used in production processes, changes in the ordering patterns of our customers, continued acceptance of and demand for our products by the markets in which we operate, introduction and/or availability of competitive products by others, potential changes in third-party reimbursement, including Medicare reimbursement as administered by the Centers for Medicare and Medicaid Services (CMS), implementation of new legislation by CMS, physician training, third-party distribution agreements, ability to execute on acquisition opportunities on favorable terms and successfully integrate any acquisitions, potential changes in applicable tax rates, legislative changes to healthcare markets and industries such as the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (including provisions such as the pending medical device tax scheduled to take effect on January 1, 2013), uncertainties related to the credit and investment markets and other factors set forth from time to time in our filings with the Securities and Exchange Commission.

All forward looking statements and cautionary statements included in this document are made as of the date hereof based on information available to us as of the date hereof, and we assume no obligation to update any forward looking statement or cautionary statement.

TABLE I  
THERAGENICS CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited)  

(In thousands except per share data)

 
           
   

Quarter Ended
September 30,

 

Nine Months Ended
September 30,

 
      2012       2011       2012       2011    
Product sales   $ 19,286     $ 20,500     $ 61,578     $ 61,206    
Licensing & fee income     630       562       1,877       1,645    
Total revenue     19,916       21,062       63,455       62,851    
Cost of sales     12,472       12,293       39,388       37,407    
Gross profit     7,444       8,769       24,067       25,444    
Operating expenses:                  
Selling, general & administrative     5,338       5,651       16,617       17,044    
Amortization of purchased intangibles     665       698       2,526       2,094    
Research & development     281       380       870       1,375    
Loss on disposal of equipment     -       2       3       4    
      6,284       6,731       20,016       20,517    
Operating income     1,160       2,038       4,051       4,927    
Non-operating items:                  
Interest income     28       39       102       122    
Interest expense     (163 )     (166 )     (482 )     (529 )  
Other     6       1       8       4    
      (129 )     (126 )     (372 )     (403 )  
Earnings before income taxes     1,031       1,912       3,679       4,524    
Income tax expense     341       771       1,217       1,740    
Net earnings   $ 690     $ 1,141     $ 2,462     $ 2,784    
Earnings per share:                  
Basic   $ 0.02     $ 0.03     $ 0.08     $ 0.08    
Diluted   $ 0.02     $ 0.03     $ 0.07     $ 0.08    
Weighted average shares:                  
Basic     29,752       33,442       32,304       33,400    
Diluted     30,383       33,727       32,911       33,766    
                                   
                                   

 

TABLE II  
THERAGENICS CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)  

(In thousands)

 
           
Assets   September 30, 2012   December 31, 2011  
Cash, cash equivalents          
& marketable securities   $ 31,770   $ 41,178  

Trade accounts receivable

    10,371     11,375  
Inventories, net     16,299     15,771  
Deferred income tax asset – current     1,118     2,028  
Refundable income taxes     106     401  
Prepaid expenses & other current assets     650     985  
Total current assets     60,314     71,738  
Property and equipment, net     32,921     34,519  
Intangible assets     11,882     9,459  
Deferred income tax asset – non current     709     -  
Other long-term assets     72     102  
Total assets   $ 105,898   $ 115,818  
           
Liabilities & Shareholders' Equity          
Accounts payable & accrued expenses   $ 5,693   $ 5,781  
Short-term borrowings     -     23,667  
Total current liabilities     5,693     29,448  
           
Long-term debt     22,000     -  
Deferred income tax liability     -     1,043  
Other long-term liabilities     1,196     1,205  
Total long-term liabilities     23,196     2,248  
           
Shareholders' equity     77,009     84,122  
Total liabilities & shareholders' equity   $ 105,898   $ 115,818  
               
               

 

TABLE III  
THERAGENICS CORPORATION AND SUBSIDIARIES  
SEGMENT INFORMATION (Unaudited)  

(In thousands)

 
                   
   

Quarter Ended
September 30,

         

Nine Months Ended
September 30,

 
      2012           2011               2012         2011    
Revenue                                  
Surgical products   $ 14,246         $ 15,280             $ 45,662         $ 45,142    
Brachytherapy seed     5,841           6,053               18,476         18,284    
      20,087           21,333               64,138         63,426    
Intersegment eliminations     (171 )         (271 )             (683 )       (575 )  
Consolidated   $ 19,916         $ 21,062             $ 63,455         $ 62,851    
                   
   

Quarter Ended
September 30,

         

Nine Months Ended
September 30,

 
      2012           2011               2012           2011    
Operating income                              
Surgical products   $ 243         $ 780             $ 1,030         $ 1,087    
Brachytherapy seed     906           1,243               3,033           3,838    
      1,149           2,023               4,063           4,925    
Intersegment eliminations     11           15               (12 )         2    
Consolidated   $ 1,160         $ 2,038             $ 4,051         $ 4,927    
                                                   
                                                   

 

TABLE IV  
THERAGENICS CORPORATION AND SUBSIDIARIES  
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (Unaudited)  

(In thousands)

 
   
EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION, AMORTIZATION AND SHARE-  
BASED COMPENSATION (ADJUSTED EBITDA)  
                           
       

Quarter Ended
September 30,

 

             

Nine Months Ended
September 30,

 
    2012         2011         2012           2011    
Net earnings, US GAAP   $ 690         $ 1,141         $ 2,462         $ 2,784    
Income tax expense   341         771         1,217           1,740    
Interest income   (28 )       (39 )       (102 )         (122 )  
Interest expense   163         166         482           529    
Other non-operating income/expense   (6 )       (1 )       (8 )         (4 )  
Operating income   1,160         2,038         4,051           4,927    
Depreciation and amortization   1,773         1,812         5,893           5,404    
Share-based compensation   246         199         685           560    
Adjusted EBITDA(a)   $ 3,179         $ 4,049         $ 10,629         $ 10,891    
                                         

(a) Represents a non-GAAP financial measure. See page 3 of this press release for information on non-GAAP financial measures. The Company currently refers to earnings before interest, taxes, depreciation, amortization and share-based compensation as "Adjusted EBITDA."

                                         
                                         

 

TABLE V  
THERAGENICS CORPORATION AND SUBSIDIARIES  
PRE-TAX CHARGES FOR SPECIAL ITEMS (Unaudited)  

(In thousands)

 
               
   

Quarter Ended
September 30,

 

     

Nine Months Ended
September 30,

 

 
    2012       2011       2012         2011  
Surgical Products Segment                              
Core receivables1   -       -       -       $ -  
Acquisition proposal expenses2   -       -       -         218  
    -       -       -       $ 218  
                       
Brachytherapy Segment                              
Core receivables1   -       -       -       $ 215  
Acquisition proposal expenses2   -       -       -         89  
    -       -       -       $ 304  
                               
Consolidated                              
Core receivables1   -       -       -       $ 215  
Acquisition proposal expenses2   -       -       -         307  
    -       -       -       $ 522  
                                 

1 Charges for accounts receivable from Core Oncology under our prior distribution agreement for which we believed collection was doubtful.

 

2 Represents expenses associated with consideration of and response to unsolicited acquisition proposal.